AEON Biopharma Inc (AMEX: AEON)’s stock price has increased by 2.43 compared to its previous closing price of 0.58. However, the company has seen a -11.55% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-03-27 that – Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to pursue another opportunity, effective April 4, 2025.
Is It Worth Investing in AEON Biopharma Inc (AMEX: AEON) Right Now?
AEON Biopharma Inc (AMEX: AEON) has a higher price-to-earnings ratio of 0.01x compared to its average ratio, The 36-month beta value for AEON is at 0.35. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AEON is 7.68M, and currently, shorts hold a 2.27% of that float. The average trading volume for AEON on April 02, 2025 was 3.39M shares.
AEON’s Market Performance
The stock of AEON Biopharma Inc (AEON) has seen a -11.55% decrease in the past week, with a -2.69% drop in the past month, and a -98.63% fall in the past quarter. The volatility ratio for the week is 9.95%, and the volatility levels for the past 30 days are at 22.25% for AEON. The simple moving average for the past 20 days is -12.08% for AEON’s stock, with a -98.90% simple moving average for the past 200 days.
Analysts’ Opinion of AEON
Many brokerage firms have already submitted their reports for AEON stocks, with H.C. Wainwright repeating the rating for AEON by listing it as a “Buy.” The predicted price for AEON in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on August 18, 2023 of the previous year 2023.
AEON Trading at -87.76% from the 50-Day Moving Average
After a stumble in the market that brought AEON to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.91% of loss for the given period.
Volatility was left at 22.25%, however, over the last 30 days, the volatility rate increased by 9.95%, as shares surge +23.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -95.18% lower at present.
During the last 5 trading sessions, AEON fell by -11.55%, which changed the moving average for the period of 200-days by -99.44% in comparison to the 20-day moving average, which settled at $0.6751. In addition, AEON Biopharma Inc saw -98.47% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AEON starting from Oleg Grodnensky, who proposed sale 201,825 shares at the price of $2.63 back on Jul 29 ’24. After this action, Oleg Grodnensky now owns shares of AEON Biopharma Inc, valued at $530,780 using the latest closing price.
Stock Fundamentals for AEON
The total capital return value is set at -6.63.
Based on AEON Biopharma Inc (AEON), the company’s capital structure generated -0.83 points at debt to capital in total, while cash flow to debt ratio is standing at -1.57.
Currently, EBITDA for the company is -27.73 million with net debt to EBITDA at -0.47. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.11.
Conclusion
In conclusion, AEON Biopharma Inc (AEON) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
